COLL Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
216.3M
+8.2%
199.9M
+3.3%
193.5M
-5.8%
205.4M
-1.9%
209.4M
Cost of Revenue
90.9M
+241.4%
26.6M
+28.0%
20.8M
-73.0%
77.1M
-3.9%
80.2M
Gross Profit
125.4M
-27.6%
173.2M
+0.3%
172.7M
+34.5%
128.4M
-0.6%
129.2M
Operating Expenses
96.7M
-43.0%
169.5M
+19.5%
141.8M
+113.4%
66.5M
-0.9%
67.1M
R&D
0
0
0
0
0
SG&A
99.6M
-6.6%
106.6M
+23.4%
86.3M
+27.7%
67.6M
+0.8%
67.1M
Operating Income
28.7M
+676.7%
3.7M
-88.0%
30.9M
-50.1%
61.9M
-0.3%
62.1M
EBITDA
84.6M
+23.5%
68.5M
-21.2%
86.8M
-26.6%
118.3M
-0.2%
118.6M
Net Income
21.8M
+244.6%
-15051000
-203.8%
14.5M
-14.5%
17.0M
-46.2%
31.5M
EPS (Basic)
$0.69
+250.0%
$-0.46
-202.2%
$0.45
-16.7%
$0.54
-46.0%
$1.00
EPS (Diluted)
$0.60
+230.4%
$-0.46
-215.0%
$0.40
+11.1%
$0.36
-57.1%
$0.84
Shares (Diluted)
39.1M
+20.5%
32.5M
-19.0%
40.1M
-15.6%
47.5M
+20.3%
39.4M
Collegium Pharmaceutical (COLL) — Financials